Perspective Therapeutics, Inc. (CATX) intrinsic value & 10-year financials
Perspective Therapeutics, Inc. (CATX) has a Graham intrinsic value of $30.99 per share. At $2.17 on Oct 17, 2026, the stock trades 93% below that value. Over the last 10 fiscal years revenue shrank 17.1% a year to $884.0K, with an average return on invested capital of -65.1%.
- Graham intrinsic value
- $30.99
- Share price (Oct 17, 2026)
- $2.17
- Price vs Graham value
- 93% below
- Market cap
- $160.2M
- Revenue (FY2025)
- $884.0K
- Revenue growth (10-yr CAGR)
- -17.1%
- ROIC (10-yr avg)
- -65.1%
- Free cash flow (FY2025)
- -$95.2M
CATX 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $884.0K | -$103.1M | -$1.40 | -$95.2M | -12846.6% | -54.8% |
| FY2024 | $1.5M | -$79.3M | -$1.23 | -$72.7M | -6250.8% | -58.9% |
| FY2023 | $1.4M | -$46.5M | -$1.74 | -$38.0M | -2855.0% | -75.9% |
| FY2022 | $0 | -$10.8M | — | -$10.7M | — | -45.9% |
| FY2021 | $10.1M | -$3.4M | — | -$3.2M | -34.3% | -84.0% |
| FY2020 | $9.7M | -$3.4M | — | -$3.9M | -35.9% | -84.8% |
| FY2019 | $7.3M | -$5.1M | — | -$5.5M | -71.8% | -82.7% |
| FY2018 | $5.9M | -$6.7M | — | -$6.0M | -113.6% | -86.1% |
| FY2017 | $4.8M | -$6.2M | — | -$6.3M | -132.5% | -46.7% |
| FY2016 | $4.8M | -$4.7M | — | -$4.4M | -106.6% | -31.0% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Perspective Therapeutics, Inc. is facing top-line stagnation, with revenue contracting over the decade.
Perspective Therapeutics, Inc. has historically struggled to out-earn its cost of capital, averaging just -65.1% ROIC.
Perspective Therapeutics, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Perspective Therapeutics, Inc. is modeled at -17.1% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $30.99 per share.